US court restrains Dr Reddy's from selling generic variant of Suboxone

The court has scheduled an expedited hearing of the preliminary injection for Thursday (June 28) and a ruling is expected soon after

Pharma major Dr Reddy’s Laboratories said on Saturday that after the launch of its generic Buprenophine and Naloxone Sublingual Film in the US market, the US district court of New Jersey issued a temporary restraint order and preliminary injunction against the company with regard to patent litigation.

Pending a hearing and decision on the injunction application filed by Indivior Plc, the court issued a temporary restraint order against Dr Reddy’s with regard to further sales and commercialisation of  the drug, which is used to treat adults with opioid dependence addition.

“The court order does not include prohibition on commercial manufacturing of the